Evidence map›Paper›PMID 39115052›Full record

ArticleFuture medicinal chemistry2024

Design, synthesis and evaluation of novel norfloxacin analogs as potent anticancer and antioxidant agents.

Faraz Qurban, Sohail Anjum Shahzad, Muhammad Saleh Khaskheli, Shafi Ullah Khan, Shujaat Ali Khan, Waqar Rauf, Shamsul Islam, Abdul Mannan

Abstract read
In one paragraph

Article in Future medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. NovelPharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Design, Synthesis, andPharmaceuticals (Basel, Switzerland) · 2025
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Faraz QurbanDepartment of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, 22060, Pakistan.ORCID 0009-0007-2320-1891
Sohail Anjum ShahzadDepartment of Chemistry, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, 22060, Pakistan.
Muhammad Saleh KhaskheliDepartment of Anesthesiology, Peoples University of Medical & Health Sciences for Women, Nawab Shah - Shaheed Benazirabad, Sindh, 67480, Pakistan.
Shafi Ullah KhanNormandie University, UNICAEN, INSERM U1086 "ANTICIPE" (Interdisciplinary Research Unit for Cancers Prevention & Treatment), Centre François Baclesse, 3 avenue Général Harris, Caen, 14000, France.
Shujaat Ali KhanDepartment of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, 22060, Pakistan.
Waqar RaufPakistan Institute of Engineering & Applied Sciences, Health Biotechnology Division, National Institute for Biotechnology & Genetic Engineering (NIBGE-C, PIEAS), Faisalabad, 38000, Pakistan.
Shamsul IslamDepartment of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, 22060, Pakistan.ORCID 0000-0002-4226-3023
Abdul MannanDepartment of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, 22060, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsAntioxidantsCell ProliferationDrug DesignMolecular Docking SimulationNorfloxacinCell SurvivalDrug Screening Assays, AntitumorHeLa CellsHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsAntioxidantsNorfloxacinantiprolifertive and antioxidant agentsdocking studiesHeLa cell linesnorfloxacin derivatives

Identifiers

PMID39115052
PMCPMC11457674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.